Orexo starts clinical study of nasal rescue medication – challenging established market

Swedish biotech firm Orexo is ready to enter the clinical stage with a nasal candidate, OX640, for the emergency treatment of allergic reactions, which includes anaphylaxis, a company press release has announced.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK still has two horses in adrenaline race
For subscribers